Form 4: Royalty Pharma EVP Acquires Shares

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, acquired 2,772 Class A Ordinary Shares through an equity performance award settlement.

Summary

• Marshall Urist, EVP, Research & Investments, acquired 2,772 Class A Ordinary Shares of Royalty Pharma plc on August 6, 2025.
• The acquisition was exempt under Rule 16b-3, related to the settlement of Equity Performance Awards.
• Following this transaction, Urist directly owns 39,256 Class A Ordinary Shares.
• Urist also indirectly owns 46,667 Class A Ordinary Shares via Sandy Lamm LLC and 19,020 via an IRA.
• The filing further details the nature of 263,412 LP interests in RPI US Partners 2019, LP, which are convertible into Class A Ordinary Shares of the Issuer at a 1:10 ratio (LP interest to Class B Interest in Holdings, then Class B to Class A Share), with no additional value required for exchange.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive, even through an award settlement, generally indicates alignment of interests and confidence in the company's performance, contributing to a moderately positive sentiment.

Positives

• Increased direct ownership by a key executive, Marshall Urist, aligning his interests with shareholders.
• The acquisition of shares stems from the settlement of Equity Performance Awards, indicating achievement of performance targets.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report, common across all industries, reflecting executive compensation and ownership changes rather than broader industry trends.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value due to increased share ownership.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive acquired shares through an equity performance award settlement. While it shows alignment of interests, it does not present new fundamental information or significant market-moving events to warrant a change in investment recommendation. It's an expected part of executive compensation.

Keywords

Royalty Pharma, RPRX, Marshall Urist, Insider Trading, SEC Form 4, Equity Performance Awards, Share Acquisition, Executive Compensation